ATTO

Attovia Therapeutics, Inc. is a biopharmaceutical company developing precision multispecific biologics to address immune-mediated and inflammatory diseases, including dermatology conditions such as atopic dermatitis and chronic pruritus, and gastroenterology disorders like inflammatory bowel disease. The company is based in San Carlos, CA. The company utilizes its proprietary Attobody platform to design novel multispecific molecules that inhibit multiple disease-driving pathways. Key pipeline candidates include ATTO-1310 (anti-IL31) and ATTO-3712 (anti-IL31 x IL13), both in phase 1 clinical trials for chronic pruritus and inflammatory skin disease, and ATTO-1091, a trispecific molecule in IND-enabling stages for inflammatory bowel disease. The company was founded in 2022 by Petter Veiby, Tao Fu, Zaneta Odrowaz. Tao Fu has been the CEO of the company since 2022.